PharmaShots | Incisive News in 3 Shots

Subscribe Now

adc therapeutics

ADC Therapeutics Reports Enrollment Completion in P-III (LOTIS-5) Study of Zynlonta Plus Rituximab for 2L+ Diffuse Large B-Cell Lymphoma

ADC Therapeutics Reports Enrollment Completion in P-III (LOTIS-5) Study of Zynlonta Plus Rituximab for 2L+ Diffuse Large B-Cell Ly...

January 1, 2025

ADC Therapeutics Announces the Results of Zynlonta in the P-II Trial for the Treatment of Follicular Lymphoma

ADC Therapeutics Announces the Results of Zynlonta in the P-II Trial for the Treatment of Follicular Lymphoma

December 13, 2023

ADC Therapeutics Voluntary Pauses Patients Enrolment in the P-II Study (LOTIS-9) of Zynlonta and Rituximab for Diffuse Large B-Cell Lymphoma

ADC Therapeutics Voluntary Pauses Patients Enrolment in the P-II Study (LOTIS-9) of Zynlonta and Rituximab for Diffuse Large B-Cel...

July 12, 2023

Insights+: The US FDA New Drug Approvals in April 2021

Insights+: The US FDA New Drug Approvals in April 2021

May 13, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us